In addition to RIP1‐Tag5 and 4T1 tumours, TNFα‐CSG (5 daily i.v. injections of 5 μg) also improved immune T‐cell infiltration into ALB‐Tag HCC (Fig EV3D). This evidence concerns the gene ALB and hepatocellular carcinoma.